Lipacreon
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Exocrine Pancreatic Insufficiency
Conditions
Exocrine Pancreatic Insufficiency, Pancreatic Diseases, Digestive System Diseases
Trial Timeline
Sep 1, 2011 → Apr 1, 2015
NCT ID
NCT01427725About Lipacreon
Lipacreon is a pre-clinical stage product being developed by Viatris for Exocrine Pancreatic Insufficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT01427725. Target conditions include Exocrine Pancreatic Insufficiency, Pancreatic Diseases, Digestive System Diseases.
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01427725 | Pre-clinical | Completed |
Competing Products
6 competing products in Exocrine Pancreatic Insufficiency
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pancrelipase in combination with Ensure Plus | Johnson & Johnson | Phase 1 | 33 |
| Pancrease MT 10.5, or MT 21 + Placebo for Pancrease MT 10.5 or MT 21 | Johnson & Johnson | Phase 3 | 77 |
| CREON | AbbVie | Approved | 85 |
| Creon IR + Creon® (DR/GR) | AbbVie | Phase 2 | 52 |
| Pancrelipase + Placebo | AbbVie | Approved | 85 |
| Pancrelipase Capsules | AbbVie | Approved | 85 |
Other Products from Viatris
Revefenacin + Tiotropium + Revefenacin Placebo + Tiotropium PlaceboApproved
82
PregabalinApproved
82
Imiquimod + DiclofenacApproved
82
gabapentin 600 mg + gabapentin 1200 mg + gabapentin 1800 mg + diazepam 20 mgApproved
82
Sulfamylon® For 5 % Topical Solution + Topical Antimicrobial/Antifungal MedicationsApproved
82